Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, during the class period from January 13, 2021, to July 28, 2024 [1][4]. Company Overview - Reckitt Benckiser Group plc is a UK-based global consumer goods company facing over 500 state and federal product liability lawsuits related to its cow's milk-based formula, Enfamil, and its competitor Abbott Laboratories' Similac [3]. Legal Allegations - The class action lawsuit claims that Reckitt made misleading statements and omissions about its business and financial condition, specifically failing to disclose the increased risk of necrotizing enterocolitis (NEC) for preterm infants consuming its formula [4]. - The lawsuit alleges that Reckitt did not adequately warn investors about the potential impact on sales and legal exposure related to the NEC risk associated with its products [4].

Core Viewpoint - Reckitt Benckiser Group PLC is facing a class action lawsuit from investors due to alleged misleading statements and failure to disclose health risks associated with its Enfamil infant formula, leading to significant stock price declines [3][4][5]. Group 1: Class Action Details - The class action represents investors who purchased Reckitt Benckiser securities between January 13, 2021, and July 28, 2024, with a deadline for filing a lead plaintiff motion set for August 4, 2025 [1]. - The lawsuit claims that Reckitt Benckiser did not adequately warn consumers and investors about the increased risk of Necrotizing Enterocolitis (NEC) for preterm infants consuming its cow's milk-based formula [3]. Group 2: Legal Outcomes and Financial Impact - A jury verdict on March 15, 2024, found Mead Johnson negligent, resulting in a $60 million award for failing to warn about NEC risks, which caused Reckitt Benckiser's American Depositary Shares (ADSs) to drop nearly 14% [4]. - Following a related case on July 29, 2024, where a Missouri jury awarded $495 million in damages over NEC caused by a competing formula, Reckitt Benckiser's ADSs fell nearly 9% [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging misleading statements related to the company's cow's milk-based formula, Enfamil, which may have increased health risks for preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The complaint claims that Reckitt failed to disclose that preterm infants were at an increased risk of developing NEC from consuming Enfamil [1]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of August 4, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Reckitt's cow's milk-based formula, Enfamil, increased the risk of preterm infants developing NEC, which was not disclosed [2] - It is alleged that the defendants made materially false and misleading statements regarding the company's business and sales prospects, particularly concerning Enfamil [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTCQX: RBGLY) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team:https:/ ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements and omissions concerning the company's cow's milk-based formula, Enfamil, which allegedly increased the risk of NEC in preterm infants [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt failed to disclose the increased risk of NEC for preterm infants consuming Enfamil, the impact on sales, and the exposure to legal claims, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of August 4, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its cow's milk-based formula, Enfamil, which is linked to increased risks for preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The allegations include that Reckitt failed to disclose the increased risk of necrotizing enterocolitis (NEC) for preterm infants consuming Enfamil, which could impact sales and expose the company to legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 4, 2025, to potentially be appointed as lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices, ensuring companies adhere to responsible business practices [3].

Financial Performance - Reckitt Benckiser expects higher revenue growth from its core brands this year [1] - Reckitt Benckiser initiated a £1 billion share buyback program [1]

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a securities class action lawsuit against Reckitt Benckiser Group PLC, alleging misleading statements regarding the risks associated with its cow's milk-based formula, Enfamil, during the Class Period from January 13, 2021, to July 28, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit asserts claims under the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), on behalf of individuals who purchased Reckitt American Depositary Shares (ADSs) during the Class Period [1]. - The case is titled Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., Case No. 1:25-cv-4708 [1]. Group 2: Allegations Against Reckitt - The Class Action alleges that Reckitt failed to disclose that preterm infants consuming its Enfamil formula were at an increased risk of developing necrotizing enterocolitis (NEC) [3]. - It is claimed that Reckitt did not adequately warn investors about the potential impact on sales and legal exposure related to the NEC risk [3]. Group 3: Market Reactions - On March 15, 2024, following a jury verdict in a related NEC lawsuit, Reckitt's ADS price fell by $1.87, or nearly 14%, from $13.31 to $11.44 per share [4]. - On July 29, 2024, after another jury verdict against Abbott Laboratories regarding NEC, Reckitt's ADS price dropped by $1.02, or nearly 9%, from $11.66 to $10.64 per share [5].

NEW YORK, July 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADSs") of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 through July 28, 2024, both dates inclusive (the "Class Period"), of the important August 4, 2025 lead plaintiff deadline.So What: If you purchased Reckitt ADSs you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to ...